Inclusion Criteria:  Documented HIV infection ≥18 of age at time of initial screening HIV suppression with HIV RNA <200 copies/ml on stable ART for ≥ 6 months and no change in ART class for ≥ 3 months, prior to enrollment Histologically confirmed NAFLD (defined as NAFL [>5% steatosis, with or without lobular or portal inflammation], borderline NASH or definitive NASH) within 6 months prior to start of screening Willingness to be in the study for 1 or more years Provision of written informed consent  Exclusion Criteria:  Positive hepatitis B surface antigen Evidence of recent or current hepatitis C virus (HCV) as marked by the presence of anti-HCV antibody with detectable HCV RNA in serum within 3 years prior to enrollment. Participants with anti-HCV antibody positivity who have undetectable HCV RNA 3 years prior to enrollment (either due to spontaneous clearance or clearance with treatment) will be eligible to participate if HCV RNA at entry remains undetected Significant alcohol consumption (≥ 3 drinks daily on average in men and ≥ 2 drinks daily on average in women) Evidence of other causes of chronic liver disease History of prolonged (> 1 month) total parenteral nutrition within a 6 month period before baseline liver biopsy Short bowel syndrome History of biliopancreatic diversion History of bariatric surgery within 2 years of enrollment (participants expecting to undergo bariatric surgery can be enrolled prior to the procedure) Solid organ transplant recipients Other condition that is likely to interfere with study follow-up